AI Article Synopsis
- - Cancer cells are more reliant on antioxidant activities than normal cells, making them vulnerable to oxidative damage, which can be exploited for treatment.
- - The study introduces a new Srx inhibitor, K27, which increases oxidative stress in cancer cells by causing the accumulation of sulfinylated peroxiredoxins, leading to cell death and mitochondrial damage.
- - K27 selectively kills tumor cells while sparing non-tumor cells and effectively inhibits tumor growth in vivo without causing acute toxicity, indicating that targeting Srx could be a promising cancer therapy approach.
Article Abstract
Cancer cells have been suggested to be more susceptible to oxidative damages and highly dependent on antioxidant capacity in comparison with normal cells, and thus targeting antioxidant enzymes has been a strategy for effective cancer treatment. Sulfiredoxin (Srx) is an enzyme that catalyzes the reduction of sulfinylated peroxiredoxins and thereby reactivates them. In this study we developed a Srx inhibitor, K27 (N-[7-chloro-2-(4-fluorophenyl)-4-quinazolinyl]-N-(2-phenylethyl)-β-alanine), and showed that it induces the accumulation of sulfinylated peroxiredoxins and oxidative stress, which leads to mitochondrial damage and apoptotic death of cancer cells. The effects of K27 were significantly reversed by ectopic expression of Srx or antioxidant N-acetyl cysteine. In addition, K27 led to preferential death of tumorigenic cells over non-tumorigenic cells, and suppressed the growth of xenograft tumor without acute toxicity. Our results suggest that targeting Srx might be an effective therapeutic strategy for cancer treatment through redox-mediated cell death.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.freeradbiomed.2016.11.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!